Aetna Policy Update Expands TMS Availability for Adolescents With Depression
Neuronetics, Inc. (NASDAQ: STIM) announced that Aetna has expanded its TMS (transcranial magnetic stimulation) coverage to include adolescents aged 15 and older with major depressive disorder (MDD). This update follows the recent FDA clearance of NeuroStar TMS as the first and only TMS treatment cleared as a first-line add-on for adolescents aged 15-21. Aetna, covering over 19.4 million lives through commercial policies, has made this policy update effective immediately.
The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA labeled indications. This policy update aligns with recent momentum from both commercial and government payers to expand adolescent coverage for TMS Therapy, including updates from Medi-Cal and Humana.
Neuronetics, Inc. (NASDAQ: STIM) ha annunciato che Aetna ha esteso la sua copertura TMS (stimolazione magnetica transcranica) per includere gli adolescenti di 15 anni e oltre affetti da disturbo depressivo maggiore (MDD). Questo aggiornamento segue l'approvazione recente da parte della FDA del NeuroStar TMS come primo e unico trattamento TMS autorizzato come terapia aggiuntiva di prima linea per gli adolescenti di età compresa tra 15 e 21 anni. Aetna, che copre oltre 19,4 milioni di persone tramite polizze commerciali, ha reso immediatamente efficace questo aggiornamento della polizza.
I criteri di copertura specificano che il trattamento TMS deve essere somministrato mediante un dispositivo approvato dalla FDA in conformità con le indicazioni etichettate dalla FDA. Questo aggiornamento della polizza è in linea con il recente slancio sia da parte dei pagatori commerciali che governativi per ampliare la copertura per la terapia TMS per gli adolescenti, inclusi aggiornamenti da Medi-Cal e Humana.
Neuronetics, Inc. (NASDAQ: STIM) anunció que Aetna ha ampliado su cobertura de TMS (estimulación magnética transcraneal) para incluir a adolescentes de 15 años o más con trastorno depresivo mayor (MDD). Esta actualización sigue a la reciente aprobación de la FDA del NeuroStar TMS como el primer y único tratamiento TMS autorizado como una terapia complementaria de primera línea para adolescentes de 15 a 21 años. Aetna, que cubre a más de 19.4 millones de personas a través de pólizas comerciales, ha hecho efectivo este cambio de política de inmediato.
Los criterios de cobertura especifican que el tratamiento TMS debe ser administrado por un dispositivo aprobado por la FDA de acuerdo con las indicaciones señaladas por la FDA. Esta actualización de la política se alinea con el reciente impulso tanto de pagadores comerciales como gubernamentales para expandir la cobertura de la terapia TMS para adolescentes, incluidos los cambios de Medi-Cal y Humana.
Neuronetics, Inc. (NASDAQ: STIM)는 Aetna가 TMS(경두개 자극 치료) 보장을 정신적 우울증(DMD)을 앓고 있는 15세 이상의 청소년으로 확대했다고 발표했습니다. 이번 업데이트는 NeuroStar TMS가 15세에서 21세까지의 청소년을 위한 1차 보조 치료로 승인된 첫 번째이자 유일한 TMS 치료법으로 FDA의 승인을 받은 이후에 이루어졌습니다. Aetna는 상업적 보험을 통해 1940만 명 이상의 생명을 보장하고 있으며, 이 정책 업데이트는 즉시 효력이 발생합니다.
보장 기준에 따르면 TMS 치료는 FDA가 승인을 한 장치를 사용하여 FDA의 라벨링 지침에 따라 실시되어야 합니다. 이 정책 업데이트는 청소년 TMS 치료에 대한 보장을 확장하기 위한 최근의 상업적 및 정부 지급자의 동향과 일치하며, Medi-Cal 및 Humana의 업데이트가 포함됩니다.
Neuronetics, Inc. (NASDAQ: STIM) a annoncé qu'Aetna a élargi sa couverture TMS (stimulation magnétique transcrânienne) pour inclure les adolescents âgés de 15 ans et plus atteints de trouble dépressif majeur (MDD). Cette mise à jour fait suite à l'approbation récente par la FDA de NeuroStar TMS comme première et unique traitement TMS autorisé comme traitement de première ligne complémentaire pour les adolescents âgés de 15 à 21 ans. Aetna, qui couvre plus de 19,4 millions de personnes par l'intermédiaire de polices commerciales, a rendu cette mise à jour de politique immédiatement effective.
Les critères de couverture spécifient que le traitement TMS doit être administré par un dispositif approuvé par la FDA conformément aux indications étiquetées par la FDA. Cette mise à jour de politique s'aligne avec le récent élan des payeurs commerciaux et gouvernementaux pour élargir la couverture de la thérapie TMS pour les adolescents, y compris les mises à jour de Medi-Cal et Humana.
Neuronetics, Inc. (NASDAQ: STIM) gab bekannt, dass Aetna seine TMS (transkranielle Magnetstimulation) Deckung erweitert hat, um Jugendliche ab 15 Jahren mit schwerer depressiver Störung (MDD) einzuschließen. Dieses Update folgt der kürzlichen FDA-Zulassung des NeuroStar TMS als erste und einzige TMS-Behandlung, die als Erstlinienzusatz für Jugendliche im Alter von 15 bis 21 Jahren freigegeben wurde. Aetna, welche über 19,4 Millionen Personen durch gewerbliche Policen abdeckt, hat diese Regelung sofort in Kraft gesetzt.
Die Deckungskriterien geben an, dass die TMS-Behandlung mit einem von der FDA zugelassenen Gerät gemäß den von der FDA gekennzeichneten Indikationen durchgeführt werden muss. Dieses Policy-Update steht im Einklang mit dem aktuellen Trend sowohl von privaten als auch von staatlichen Kostenträgern, die TMS-Therapien für Jugendliche zu erweitern, einschließlich der Aktualisierungen von Medi-Cal und Humana.
- Aetna expanded TMS coverage to include adolescents aged 15 and older with MDD
- NeuroStar TMS received FDA clearance as first-line add-on for adolescents aged 15-21
- Aetna's policy update is effective immediately, potentially increasing market access
- Neuronetics is the only TMS company with FDA clearance for adolescent treatment
- Recent momentum from commercial and government payers expanding adolescent TMS coverage
- None.
Coverage criteria consistent with recent FDA clearance for NeuroStar TMS
MALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that Aetna has updated its TMS (transcranial magnetic stimulation) coverage to include adolescents aged 15 and older with MDD (major depressive disorder). This expanded access follows the recent clearance from the U.S. Food and Drug Administration (FDA) for NeuroStar TMS as the first and only TMS treatment cleared as a first-line add-on for adolescents aged 15-21.
The coverage criteria specify that TMS treatment must be administered by an FDA-cleared device in accordance with FDA labeled indications. Aetna is one of the largest health plans in the country with over 19.4 million lives covered through its commercial policies nationwide. The TMS policy update is effective immediately.
“We commend Aetna for being a leader among payors in recognizing the critical need to reduce barriers to proven treatments for adolescent mental health,” stated Keith J. Sullivan, President and CEO of Neuronetics, Inc. “Enabling earlier access to NeuroStar TMS as part of an individual’s care plan is a significant step payors can take toward helping to mitigate the mental health crisis affecting young people.”
This policy update builds on recent momentum from both commercial and government payers to expand adolescent coverage for TMS Therapy. Neuronetics previously announced updated policies through payers such as Medi-Cal and Humana. In addition to being the first and only TMS company with FDA clearance for adolescent treatment, Neuronetics is the only TMS company in the industry with a dedicated health policy team that partners with both providers and payors to advocate for health policy updates.
For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.
About Adolescent Depression
Adolescent depression is a complex and challenging mental health condition that affects young individuals during the crucial period of adolescence. An estimated 4.3 million U.S. adolescents aged 15-21 are affected by MDDi. Depression amongst adolescents can disrupt crucial aspects of development, such as academic performance, relationships with peers and family members, and overall emotional well-being.
NeuroStar Advanced Therapy is indicated as an adjunct for the treatment of MDD in adolescent patients aged 15-21.
About Neuronetics
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.4 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.
Media Contact:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com
iWorld Health Organization, Depression Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/depression.
FAQ
What is the new Aetna policy update for TMS treatment?
What recent FDA clearance did NeuroStar TMS receive for adolescent treatment?
How many lives does Aetna cover through its commercial policies?
What is Neuronetics' stock symbol?
Which other payers have recently updated their policies for adolescent TMS coverage?
